Interaction Checker

Interaksi Epoprostenol

Epoprostenol (Flolan, Veletri), golongan analog prostaglandin, memiliki 162 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 13 mayor, 141 moderat, 8 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (13)

  • ApiksabanantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • ArgatrobanantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • BivalirudinantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • DabigatranantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • Diklofenak dan misoprostolOAINSMayor

    …fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.8 , 5.9) ] • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see Warnings and Precautions (5.8 , 5.10) ] • Pregnancy ( 4 ) (label Diklofenak dan misoprostol, Kontraindikasi)

  • EdoksabanantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • EnoksaparinantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • FondaparinuksantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • HeparinantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • KetorolakOAINSMayor

    Ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage. (label Ketorolak, Kontraindikasi)

  • Latanoprostanalog prostaglandinMayor

    The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (label Latanoprost, Interaksi obat)

  • RivaroksabanantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

  • WarfarinantikoagulanMayor

    Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (label Epoprostenol, Peringatan dan perhatian)

Interaksi moderat (141)

  • AdenosinantiaritmiaModerat

    Hypotension Adenosine injection is a potent peripheral vasodilator and can induce significant hypotension. (label Adenosin, Peringatan dan perhatian)

  • AliskirenantihipertensiModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Alprostadilanalog prostaglandinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Amiloriddiuretik hemat kaliumModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Asam etakrinatdiuretik loopModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Asam mefenamatOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Asam mefenamat, Peringatan dan perhatian)

  • Asebutololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Asetazolamidpenghambat karbonat anhidraseModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • AspirinOAINSModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Aspirin dan dipiridamolantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Atenololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Atenolol dan klortalidonpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Avanafilpenghambat PDE5Moderat

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (label Avanafil, Peringatan dan perhatian)

  • Azilsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Benazeprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Betaksololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Bisoprololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Bisoprolol dan hidroklorotiazidpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Bumetaniddiuretik loopModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Butalbital, aspirin, dan kafeinbarbituratModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Butalbital, aspirin, kafein, dan kodeinbarbituratModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Deksmedetomidinagonis alfa-adrenergikModerat

    • Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. (label Deksmedetomidin, Peringatan dan perhatian)

  • DiflunisalOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Diflunisal, Peringatan)

  • Digoksinglikosida digitalisModerat

    In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n=23) and digoxin (n=30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. (label Epoprostenol, Interaksi obat)

  • DiklofenakOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Diklofenak, Peringatan dan perhatian)

  • Diltiazempenghambat kanal kalsiumModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • DipiridamolantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Doksazosinpenyekat alfaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Enalaprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Enalaprilatpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Eplerenonantagonis aldosteronModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • EptifibatidantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • EtodolakOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Etodolak, Peringatan)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Fenoksibenzaminpenyekat alfaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • FenoprofenOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Fenoprofen, Peringatan dan perhatian)

  • FlurbiprofenOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Flurbiprofen, Peringatan dan perhatian)

  • Fosinoprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Furosemiddiuretik loopModerat

    In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n=23) and digoxin (n=30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. (label Epoprostenol, Interaksi obat)

  • Guanfasinagonis alfa-adrenergikModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • HidralazinvasodilatorModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Hidroklorotiaziddiuretik tiazidModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Hidrokodon dan ibuprofenopioidModerat

    Renal Toxicity and Hyperkalemia Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Hidrokodon dan ibuprofen, Peringatan)

  • IbuprofenOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Ibuprofen, Peringatan dan perhatian)

  • Ibuprofen dan famotidinOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Ibuprofen dan famotidin, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • IndometasinOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Indometasin, Peringatan dan perhatian)

  • Irbesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Isosorbid dinitratnitratModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Isosorbid dinitrat dan hidralazinnitratModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Isosorbid mononitratnitratModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Kandesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • KangrelorantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Kaptoprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Karvedilolpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • KetoprofenOAINSModerat

    A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (label Ketoprofen, Peringatan dan perhatian)

  • Klonidinagonis alfa-adrenergikModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • KlopidogrelantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Klorotiaziddiuretik tiazidModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Klortalidondiuretik tiazidModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Kuinaprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Labetalolpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Lisinoprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Lofeksidinagonis alfa-adrenergikModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Losartanpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • MekamilaminantihipertensiModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • MeloksikamOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Meloksikam, Peringatan dan perhatian)

  • MetildopaantihipertensiModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Metilergometrinalkaloid ergotModerat

    Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (label Metilergometrin, Interaksi obat)

  • Metolazondiuretik tiazidModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Metoprololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Metoprolol dan hidroklorotiazidpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • MinoksidilvasodilatorModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Moeksiprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • NabumetonOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Nabumeton, Peringatan)

  • Nadololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • NaproksenOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Naproksen, Peringatan dan perhatian)

  • Naproksen dan esomeprazolOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Naproksen dan esomeprazol, Peringatan dan perhatian)

  • Nebivololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • NitrogliserinnitratModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • NitroprusidvasodilatorModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • OksaprozinOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Oksaprozin, Peringatan dan perhatian)

  • Olmesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Orfenadrin, aspirin, dan kafeinpelemas ototModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • PapaverinvasodilatorModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Parasetamol dan ibuprofenOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Parasetamol dan ibuprofen, Peringatan dan perhatian)

  • Perindoprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Pindololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • PiroksikamOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Piroksikam, Peringatan dan perhatian)

  • PrasugrelantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Prazosinpenyekat alfaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Propranololpenyekat betaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Ramiprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • RiosiguatvasodilatorModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • SalsalatOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Salsalat, Peringatan)

  • SelekoksibOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Selekoksib, Peringatan dan perhatian)

  • Sildenafilpenghambat PDE5Moderat

    Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (label Sildenafil, Peringatan dan perhatian)

  • SilostazolantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Spironolaktonantagonis aldosteronModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • SulindakOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. (label Sulindak, Peringatan)

  • Sumatriptan dan naproksentriptanModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Sumatriptan dan naproksen, Peringatan dan perhatian)

  • Tadalafilpenghambat PDE5Moderat

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (label Tadalafil, Peringatan dan perhatian)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Terazosinpenyekat alfaModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • TikagrelorantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • TirofibanantiplateletModerat

    When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

  • Tizanidinpelemas ototModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • TolmetinOAINSModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Tolmetin, Peringatan)

  • Torasemiddiuretik loopModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Trandolaprilpenghambat ACEModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Treprostinilanalog prostaglandinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Triamterendiuretik hemat kaliumModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Vardenafilpenghambat PDE5Moderat

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (label Vardenafil, Peringatan dan perhatian)

  • Verapamilpenghambat kanal kalsiumModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • VerisiguatvasodilatorModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

Penyebutan minor (8)

  • Alfuzosinpenyekat alfaMinor

    Phosphodiesterase-5 (PDE5) Inhibitors: PDE5-inhibitors are also vasodilators. (label Alfuzosin, Peringatan dan perhatian)

  • Dutasterid dan tamsulosinpenghambat 5-alfa reduktaseMinor

    Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure. (label Dutasterid dan tamsulosin, Peringatan dan perhatian)

  • EpinefrinsimpatomimetikMinor

    Drugs antagonizing pressor effects of epinephrine α-blockers, such as phentolamine Vasodilators, such as nitrates Diuretics Antihypertensives Ergot alkaloids Drugs potentiating pressor effects of epinephrine • Sympathomimetics • β-blockers, such as propranolol • Tricyclic anti-depressants • Monoamine oxidase (MAO) inhibitors • Catechol-O-methyl transferase (COMT)… (label Epinefrin, Interaksi obat)

  • Kalium kloridasuplemen kaliumMinor

    Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)

  • Karboprostanalog prostaglandinMinor

    Evidence from animal studies has suggested that certain other prostaglandins have some teratogenic potential. (label Karboprost, Peringatan)

  • MetoheksitalbarbituratMinor

    Post injury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. (label Metoheksital, Peringatan)

  • Silodosinpenyekat alfaMinor

    Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (label Silodosin, Peringatan dan perhatian)

  • Tamsulosinpenyekat alfaMinor

    Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (label Tamsulosin, Peringatan dan perhatian)

Periksa Epoprostenol terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.